Cancer Immunotherapy Sees Setback With Failure Of Cell Genesys’ GVAX
Cell Genesys will cut 75 percent of its workforce and explore strategic alternatives after halting development of the prostate cancer vaccine.
Cell Genesys will cut 75 percent of its workforce and explore strategic alternatives after halting development of the prostate cancer vaccine.